Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 1

Status

Recruiting 20Completed 20Terminated 7Active not recruiting 7Unknown 6Withdrawn 5

Sponsor Class

OTHER 4OTHER_GOV 1INDUSTRY 1

Study Type

Observational 7Interventional 6

Sponsor

Cancer Type

Endocrine 6CNS 6NET 2

Conditions

Breast Neoplasms 1275Carcinoma, Non-Small-Cell Lung 783Neoplasms 767Colorectal Neoplasms 755Carcinoma, Hepatocellular 579Stomach Neoplasms 578Prostatic Neoplasms 501Lung Neoplasms 461Pancreatic Neoplasms 416Rectal Neoplasms 331Recurrence 312Neoplasm Metastasis 305Leukemia, Myeloid, Acute 289Multiple Myeloma 281Colonic Neoplasms 280Lymphoma 273Uterine Cervical Neoplasms 269Esophageal Neoplasms 267Ovarian Neoplasms 261Head and Neck Neoplasms 246Melanoma 240Precursor Cell Lymphoblastic Leukemia-Lymphoma 209Brain Neoplasms 195Lymphoma, Large B-Cell, Diffuse 184Nasopharyngeal Carcinoma 180Lymphoma, Non-Hodgkin 173Leukemia 173Liver Neoplasms 163Glioblastoma 158Urinary Bladder Neoplasms 153

Interventions

anlotinib 2lutetium Lu 177 dotatate 1Temozolomide 190Y-octreotate, DOTA(0)-Tyr(3)-Thr(8)- 13-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Unknown × Interventional × Paraganglioma × Clear all
NCT05885386 2023-06-01

A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL

Peking Union Medical College Hospital

Phase 2 Unknown
20 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT05883085 2023-05-31

A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL

Peking Union Medical College Hospital

Phase 2 Unknown
10 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT05133349 2021-11-24

EASOAIPPGL

Nanjing First Hospital, Nanjing Medical University

Phase 2 Unknown
20 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT04029428 2020-04-01

POLNETS_PRRT

University of Warmia and Mazury

Phase 2 Unknown
150 enrolled
CNSEndocrineNET

Paraganglioma, Neuroendocrine Tumors

NCT00874614 2020-02-20

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Phase 2 Unknown
74 enrolled 10 charts 1 FDA
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT01373736 2011-06-15

123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors

Vancouver Coastal Health

Phase 3 Unknown
CNSEndocrine

Carcinoid Tumor, Neuroblastoma, Paraganglioma, Pheochromocytoma, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡